Replies to post #11432 on Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

I think you missed my point. Not saying they will or won't, just saying I don't think those Synthon trial results mean squat to the FDA regarding an interchangeable AB rated generic Copaxone. Like I said, I bet Natco's copax knock off in India would do a-okay in trials (they're not using the same one for their ANDA), but no way in hell that version would get approved by the FDA.

As a side regarding Amphastar, of course there's that whole thing were Amphastar used MNTA's technology to get approved and all :P

[mouton29]

If this is evidence of the ease of replication of Copaxone, why are TEVA and MNTA marginally up on a down day. Dead cat bounce?